RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (Australia), Fast Track (South Korea), Priority Review (Taiwan Province), Priority Review (United States), Conditional marketing approval (China), Priority Review (China), Breakthrough Therapy (United States)

Structure/Sequence

Boost your research with our ADC technology data.

view full example data

Sequence Code 27958L

Source: *****

Sequence Code 319372635H

Source: *****

130

Clinical Trials associated with Sacituzumab govitecan-hziy

NCT07339059

/ Not yet recruitingPhase 2IIT

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination.
The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors.
Participants in the trial will:
* receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient.
* CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks.
* provide tissue (optional) and blood for additional testing (learn about the cancer).

Start Date01 Feb 2026

Sponsor / Collaborator

Henry Ford Health System

[+1]

CTIS2025-521489-80-00

/ Not yet recruitingPhase 2

A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)

Start Date31 Jan 2026

Sponsor / Collaborator-

NCT07178730

/ Not yet recruitingPhase 3IIT

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes. Preoperative chemotherapy is the standard of care for patients with stage II or III primary TNBC. Multiple lines of clinical evidence demonstrate that TNBC patients who achieve a pCR to NACT, (ypT0/is ypN0), have an excellent long-term prognosis. A meta-analysis of individual patient data confirmed a strong association of pCR after NACT with improved long-term event-free survival (EFS, hazard ratio [HR] 0.24) and overall survival (OS, HR 0.16) benefit. Taxane- and anthracycline-based neoadjuvant regimens generally result in pCR rates between 25-50% [REFs], whereas the addition of platinum increases pCR rates to approximately 50-55%.
The KEYNOTE-522 trial has demonstrated that the addition of the immune-checkpoint inhibitor PEM to anthracycline- (AC), taxane- and platinum-based NACT resulted in a significant increase in pCR rates to nearly 65%, associated with a significant reduction of recurrences (EFS, HR 0.65 at 5 years) and improvement of OS (HR 0.66). Based on these results, the KEYNOTE-522 regimen has been approved by the FDA and EMA and has become the standard of care for patients with stage II or III TNBC.
Despite this significant progress, two major questions remain unresolved which will be investigated in the ADAPT-TN-IV trial:
1. Do all patients require the full 6 months of NACT as per KEYNOTE-522 or is there a subgroup of patients who are sufficiently treated with 12 weeks of NACT plus PEM?
2. Can incorporation of ADCs into the KEYNOTE-522 regimen improve response and outcomes in patients without an optimal early response? The outcome of patients with residual disease after 24 weeks of NACT and PEM remains suboptimal and there is an urgent need for more effective strategies. ADCs such as SG have demonstrated superior efficacy compared to standard chemotherapy in metastatic TNBC, resulting in substantially higher response rates and improved progression-free (PFS) and OS. Combination studies of ADCs and immunotherapy in metastatic TNBC have demonstrated significant activity, suggesting possible synergistic activity It is therefore a logical next step to investigate, whether the incorporation of SG in the NACT regimen can improve pCR rates and EFS results in patients who have residual clinical disease after 12 weeks of NACT with CARBO/PAC + PEM.

Start Date31 Jan 2026

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with Sacituzumab govitecan-hziy

100 Translational Medicine associated with Sacituzumab govitecan-hziy

100 Patents (Medical) associated with Sacituzumab govitecan-hziy

2,008

Literatures (Medical) associated with Sacituzumab govitecan-hziy

01 Feb 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies

Review

Author: Maniam, Akash ; Hettiarachchige Don, Anton ; Perera, Anne ; Banna, Giuseppe Luigi ; Atsumi, Naoko

This review explores the therapeutic potential of Antibody-Drug Conjugates (ADC) in urological malignancies, emphasizing treatment efficacy, safety, and future prospects. ADC selectively deliver cytotoxic agents to cancer cells, reducing off-target toxicity compared to conventional therapies. Comprising a monoclonal antibody (mAb) linked to a cytotoxic payload, ADC exert their effects through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). This review highlights ADC advancements in urothelial cancer (UC), prostate cancer (PC), and renal cell carcinoma (RCC). Recent trials demonstrate encouraging outcomes with ADC such as Enfortumab Vedotin (EV), Sacituzumab Govitecan (SG), Trastuzumab Deruxtecan (T-DXd), and Disitamab Vedotin (DV) in UC, improving response rates and Progression-Free Survival (PFS). The influence of antigen expression, particularly Nectin-4 and Trop-2, on ADC treatment outcomes is investigated. In addition, efficacy and safety of ADC combinations with anti-PD-(L)1 therapies and dual immune checkpoint inhibitors to further enhance therapeutic benefit are explored. In PC, ADC targeting prostate-specific membrane antigen (PSMA), Trop-2, and B7-H3 exhibit promising antitumor activity, with research optimizing safety, efficacy, and monitoring strategies. In RCC, ADC against ENPP3, CD70, and TIM-1 show durable responses in early trials, though challenges such as dose-limiting toxicities require further investigation. Overall, this review underscores ADC as a transformative approach in uro-oncology, highlighting ongoing advancements in combination strategies and biomarker-driven applications to refine therapeutic outcomes and expand treatment options for these challenging malignancies.

01 Feb 2026·CANCER TREATMENT REVIEWS

Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer

Review

Author: Naidoo, Jarushka ; Gadgeel, Shirish ; Mino-Kenudson, Mari ; Sethakorn, Nan ; Patel, Sandip Pravin

Lung cancer remains the leading cause of cancer-related death in the United States, with non-small cell lung cancer (NSCLC) accounting for most lung cancer cases. Improvements in first-line treatment with immuno-oncology and targeted therapies have been observed in patients with NSCLC, but benefits may be limited for those with advanced or metastatic NSCLC (mNSCLC). Following progression on frontline therapies, later-line therapies offer modest benefits and are associated with pronounced adverse effects. Accordingly, there is a need for new, more effective options to improve survival and quality of life. Trophoblast surface antigen 2 (TROP2) antibody-drug conjugates (ADCs) are a novel approach to address unmet treatment needs in NSCLC. There are 5 TROP2-directed ADCs currently under investigation for treatment of NSCLC: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan, DB-1305, and SHR-A1921. Here, we provide an overview of the properties of each ADC as well as efficacy and safety data from clinical trials of patients with NSCLC with or without actionable genomic alterations (AGAs). The unique characteristics of each ADC and its components, particularly the linker chemistry and payload attributes, define the mechanism of action and subsequently influence dosing, efficacy, and safety. TROP2 ADCs have shown antitumor responses with a manageable safety profile in patients with mNSCLC in several ongoing and completed trials. Additional studies are required to understand how these agents can be effectively integrated into the treatment paradigm for lung cancer, taking into consideration sequential use of multiple ADCs, resistance mechanisms, combination therapies, and use in special populations.

01 Feb 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

TROP-2–directed antibody–drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes

Review

Author: Siddiqui, Hafiza Tooba ; Rath, Shree ; Alam, Umama ; Ansab, Muhammad ; Desai, Aakash ; Burhan, Muhammad

INTRODUCTION:

Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases worldwide, with most patients diagnosed at advanced stages and limited by resistance to existing therapies. TROP-2, an epithelial cell surface glycoprotein overexpressed in many NSCLCs, has emerged as a promising therapeutic target for antibody-drug conjugates (ADCs). This study aims to systematically evaluate the efficacy and safety of TROP-2-directed ADCs in patients with advanced or metastatic NSCLC.

METHODS:

Electronic databases (PubMed, Embase, Clinical Trials and Cochrane Central) were searched up to November 2025 for studies reporting outcomes in advanced NSCLC patients treated with TROP-2-directed ADCs. Eligible studies included adult populations with advanced NSCLC that were treated with datopotamab deruxtecan, sacituzumab govitecan, or sacituzumab tirumotecan, and reported efficacy or safety outcomes. Pseudo-individual patient-level data for survival analyses were reconstructed from published Kaplan-Meier curves. Pooled effect sizes were estimated using random-effects meta-analytic models.

RESULTS:

Seven studies encompassing 1365 patients with advanced or metastatic NSCLC were included. The pooled median overall survival (OS) was 16.38 months (95 % CI: 11.17-22.96), and the median progression-free survival (PFS) was 6.08 months (95 % CI: 4.93-8.55). The objective response rate (ORR) across studies was 29 % (95 % CI: 19 %-39 %), with a disease control rate (DCR) of 79 % (95 % CI: 74 %-84 %). Subgroup analysis revealed patients with EGFR-mutated tumors had a significantly higher likelihood of response (risk ratio 1.70, 95 % CI: 1.11-2.61). Safety analysis showed treatment-emergent adverse events (TEAEs) in 98 % (95 % CI: 94 %-100 %), grade ≥ 3 TEAEs in 52 % (95 % CI: 38 %-67 %), and interstitial lung disease (ILD) in 9 % (95 % CI: 3 %-16 %).

CONCLUSION:

TROP-2-directed ADCs demonstrate meaningful efficacy in previously treated advanced NSCLC, especially among EGFR-mutant and non-squamous histology patients, with survival and response outcomes superior to traditional chemotherapy. However, high rates of adverse events, particularly ILD, necessitate close monitoring. Further randomized and biomarker-driven studies are warranted to refine patient selection and optimize the therapeutic potential of these agents.

491

News (Medical) associated with Sacituzumab govitecan-hziy

23 Jan 2026

·www.biospace.com

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to Therapy NEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D Path , a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences, Inc. This high-pro is evaluating a novel combination therapy for patients with locally advanced or metastatic urothelial carcinoma (mUC), including bladder cancer, and represents an important step forward in 4D Path’s mission to redefine precision oncology. The DAD-IO study builds upon the successful Phase I Double Antibody Drug Conjugate (DAD) trial, examining a regimen that combines two powerful Antibody Drug Conjugates (ADC)—Sacituzumab Govitecan (SG, from Gilead) and Enfortumab Vedotin (EV, from Seagen/Astellas)—with or without the immune checkpoint inhibitor Pembrolizumab. This approach is being studied in both treatment-naïve patients (SG+EV+Pembrolizumab) and those who have progressed on prior therapies (SG+EV). As part of the study, 4D Path will analyze pre-treatment H&E-stained biopsy slides using its proprietary Q-Plasia OncoReader™ (QPOR™) platform. By applying physics-based algorithms to whole-slide images, QPOR will generate predictive biomarkers linked to immune response, cell proliferation, and key patterns of tumor biology, helping to anticipate how patients may respond to this new combination therapy. “The responses we have seen in the Ph1b DAD study with SG+EV are certainly encouraging, but understanding why some patients don’t respond may be just as important. This digital biomarker platform offers a novel and potentially powerful way to explore mechanisms of resistance by computationally analyzing tumor biology and the immune microenvironment from routine biopsy images. These insights could help us better stratify patients with urothelial carcinoma receiving double ADC therapy—with or without immunotherapy—and potentially uncover biological patterns relevant across multiple cancer types,” said Dr. Bradley McGregor, MD, principal investigator, Dana-Farber Cancer Institute. Participation in this Dana-Farber-led, Gilead-supported study reflects growing institutional confidence in QPOR as a clinically meaningful, scalable tool for predicting therapy response. The prospective nature of the trial, alongside its rigorous scientific and clinical oversight, provides an opportunity to validate digital, image-based biomarkers in a new therapeutic context: the intersection of ADCs and immunotherapy. The collaboration also reinforces the broad applicability of 4D Path’s approach. Previous retrospective validation in phase II randomized trials in Triple Negative Breast Cancer (TNBC) has demonstrated QPOR’s impressive predictive performance across different stages of disease and treatment regimens, including chemotherapy alone and in combination with immunotherapy. Together, these studies highlight the versatility of 4D Path’s digital, image-based biomarkers across both early-stage and metastatic cancers. The DAD-IO study will extend this potential to patients with urothelial carcinoma receiving novel ADC and IO therapies. 4D Path’s participation in the DAD-IO trial exemplifies the company’s commitment to expanding access to precision medicine through non-invasive, cost-effective, and biological insights. As oncology enters an era defined by complex regimens and combination therapies, the need for early, scalable treatment predictive tools is more urgent than ever. In joining the DAD-IO study, 4D Path is taking another meaningful step toward transforming how we predict, personalize, and optimize cancer treatment. “This trial represents the next phase in advancing QPOR from retrospective promise to real-world, prospective impact,” said Satabhisa Mukhopadhyay, Ph.D., co-founder and chief scientific officer at 4D Path. “Our vision has always been to use biology-driven, physics-inspired AI to predict tumor response to chemotherapy as well as to the expanding field of chemoimmunotherapy. By extending QPOR into ADCs and immune checkpoint inhibitors, we’re helping to unlock a deeper understanding of how these therapies work, and for whom. Bladder cancer, in particular, represents an urgent frontier because it’s a cancer with limited precision tools and high unmet need. This study allows us to bring a new layer of insight to an evolving treatment landscape.” Analysis of pre-treatment biopsies is expected to begin in early 2026. The ongoing trial is expected to continue for approximately 12–18 months in total. About 4D Path 4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient’s response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life. For additional information, please visit or follow 4D Path on LinkedIn . CONTACT: PR Contact Jordan Bouclin / Jill Anderson SVM PR & Marketing Communications Jordan.bouclin@svmpr.com / Jill.anderson@svmpr.com (401) 490-970

Phase 2Immunotherapy

22 Jan 2026

·www.biospace.com

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

– Combination Reduced the Risk of Death or Disease Progression by 35% Versus Standard of Care in Frontline PD-L1+ Metastatic TNBC Setting – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine ( NEJM ) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy ® (sacituzumab govitecan-hziy) plus Keytruda ® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65; p1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes. In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes. DRUG INTERACTIONS UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY. UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY. Please see full Prescribing Information , including BOXED WARNING. About Gilead and Kite Oncology Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. U.S. Prescribing Information for Trodelvy, including BOXED WARNING , is available at . For more information about Gilead, please visit the company’s website at , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences). Contacts Ashleigh Koss, Media public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com

Clinical ResultPhase 3ADCImmunotherapy

22 Jan 2026

·www.drugs.com

Progression-Free Survival Prolonged With Sacituzumab Govitecan Plus Pembrolizumab in TNBC

THURSDAY, Jan. 22, 2026 -- For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly longer progression-free survival than chemotherapy plus pembrolizumab, according to a study published in the Jan. 22 issue of the New England Journal of Medicine . Sara M. Tolaney, M.D., from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and colleagues randomly assigned patients with previously untreated PD-L1-positive, locally advanced unresectable or metastatic TNBC to receive either sacituzumab govitecan plus pembrolizumab or chemotherapy plus pembrolizumab (221 and 222 patients, respectively). The researchers found that the median progression-free survival was 11.2 and 7.8 months with sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively (hazard ratio for disease progression or death, 0.65). Data were immature for overall survival. The percentage of patients with an objective response was 60 and 53 percent for sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively; among those with a response, the median duration of response was 16.5 and 9.2 months, respectively. Adverse events of grade 3 or higher occurred in 71 and 70 percent of patients receiving sacituzumab govitecan plus pembrolizumab and chemotherapy plus pembrolizumab, respectively; the incidence of treatment discontinuation due to adverse events was 12 and 31 percent, respectively. "The findings from the ASCENT-04/KEYNOTE-D19 and ASCENT-03 trials support the use of sacituzumab govitecan as a potential backbone treatment option, with or without pembrolizumab, for patients with previously untreated, locally advanced unresectable or metastatic triple-negative breast cancer," the authors write. The study was funded by Gilead Sciences, the manufacturer of sacituzumab govitecan, and was conducted in collaboration with Merck Sharp & Dohme. Abstract/Full Text (subscription or payment may be required)

Clinical ResultClinical Study

100 Deals associated with Sacituzumab govitecan-hziy

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sacituzumab govitecan-hziy	L01	DB12893

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic Triple-Negative Breast Carcinoma	European Union	Gilead Sciences Ireland UC	22 Nov 2021
Metastatic Triple-Negative Breast Carcinoma	Iceland	Gilead Sciences Ireland UC	22 Nov 2021
Metastatic Triple-Negative Breast Carcinoma	Liechtenstein	Gilead Sciences Ireland UC	22 Nov 2021
Metastatic Triple-Negative Breast Carcinoma	Norway	Gilead Sciences Ireland UC	22 Nov 2021
Breast Cancer	Switzerland	Gilead Sciences, Inc.	09 Sep 2021
Hormone receptor positive HER2 negative breast cancer	Australia	Gilead Sciences Pty Ltd.	06 Sep 2021
Transitional Cell Carcinoma	United States	Gilead Sciences, Inc.	13 Apr 2021
Triple Negative Breast Cancer	United States	Gilead Sciences, Inc.	22 Apr 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic breast cancer	NDA/BLA	China	Genting Pharmaceutical (Suzhou Co Ltd.	17 May 2021
Extensive stage Small Cell Lung Cancer	Phase 3	United States	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	China	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Japan	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Argentina	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Australia	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Belgium	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Brazil	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	Canada	Gilead Sciences, Inc.	04 Apr 2025
Extensive stage Small Cell Lung Cancer	Phase 3	France	Gilead Sciences, Inc.	04 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06865677 (CTgov)	Phase 2	Recurrent Cervical Cancer \| Recurrent Endometrial Cancer \| Platinum-Resistant Epithelial Ovarian Carcinoma	2	Sacituzumab Govitecan (SG) (Arm 1/Cohort 3 -Treatment With Sacituzumab Govitecan (SG))	yyfojqmthh = hkjryylnbs sttatfbiuy (ergbncovtz, ognzxnfuau - iywwzhkicr) View more	-	21 Jan 2026
NCT06865677 (CTgov)	Phase 2		2	Sacituzumab (Participants Not Assigned to an Arm/Cohort - Treatment With Sacituzumab Govitecan (SG))	yyfojqmthh = nncjwfimoz sttatfbiuy (ergbncovtz, abbblqntec - usutcunnwx) View more	-	21 Jan 2026
TREND-02 (SABCS2025)	Phase 2	Triple Negative Breast Cancer Neoadjuvant TROP-2 expression \| combined positive score (CPS)	30	Sacituzumab govitecan+tislelizumab	crjeodlaep(yloonfxcea) = mzetdcessn asvxvdjwcq (yawgertkrt )	Positive	12 Dec 2025
SABCS2025	Not Applicable	Triple Negative Breast Cancer	303	Sacituzumab govitecan (>65 years)	qgeklwsjrn(wxwaonkssk) = pqcisgwynx fnjnctkioc (keekjyvelz ) View more	Positive	12 Dec 2025
SABCS2025	Not Applicable	Triple Negative Breast Cancer	303	Sacituzumab govitecan (≤65 years)	qgeklwsjrn(wxwaonkssk) = kownrxkrxo fnjnctkioc (keekjyvelz ) View more	Positive	12 Dec 2025
SABCS2025	Not Applicable	Triple Negative Breast Cancer Second line	42	Sacituzumab govitecan (SG)	jgxpluddtt(ppjzzoxyye) = Grade 2 diarrhea occurred in 7.1%, grade 1 in 16.7%. Grade 3 and 4 neutropenia were observed in 4.8% each. Granulocyte colony-stimulating factors use was reported in 23.8% of patients. nwxnhiszmq (ztfdqrsika )	Positive	12 Dec 2025
SABCS2025	Not Applicable	Triple Negative Breast Cancer Second line	42	Sacituzumab govitecan (SG)		Positive	12 Dec 2025
NCT06236269 (SOLTI ACROSS-TROP2, SABCS2025)	Phase 2	Hormone receptor positive HER2 negative breast cancer Second line HR+ \| HER2-	50	Sacituzumab Govitecan 10 mg/kg	nycsbsvyrn(spldkadrdy) = pmzrgretro cnkfbowhje (xhpkzomupd, 0.99 - 7.65) View more	Positive	11 Dec 2025
SABCS2025	Not Applicable	Advanced breast cancer ER positive \| HER2 negative	74	Sacituzumab govitecan (SG)	cyssiilgqj(qcprsghlxt) = ghvqhpvpoe qccedorrqg (ewnkcdrrtx, 9 - 20) View more	Negative	10 Dec 2025
SABCS2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer HER2-low \| HR+ \| HER2-0	472	Sacituzumab govitecan (HR+/HER2- mBC)	smroulhnic(nggzxueyvd) = vbnssccvxz xmhslzlfhi (bmimxaovkp, 10.2 - not estimable) View more	Positive	10 Dec 2025
SABCS2025	Not Applicable		472	Sacituzumab govitecan (mTNBC)	smroulhnic(nggzxueyvd) = ewfypgrzgo xmhslzlfhi (bmimxaovkp, 13.6 - 20.3) View more	Positive	10 Dec 2025
SABCS2025	Not Applicable	Metastatic breast cancer UGT1A1*28	15	Sacituzumab Govitecan	bqxtvplapf(hnurebcgrs) = fjehnyfqhw ypoebpxpeb (gwqgegrlvt ) View more	Positive	10 Dec 2025
SABCS2025	Not Applicable	Triple Negative Breast Cancer \| Brain metastases	29	Sacituzumab govitecan	wxxkjsptnr(ixgfqggvuj) = SG administration required dose delays due to AEs in 15 patients (51.7%), and dose reductions in 11 (37.9%).Two cases (7.7%) of treatment discontinuation due to toxicity were reported. wwgtjcxljs (unkoxrtibm )	Positive	10 Dec 2025
ESMO_ASIA2025	Not Applicable	Advanced Triple-Negative Breast Carcinoma	76	Sacituzumab govitecan	etzucjihxo(wrhjpgqebs) = grrychagmd znqndatkri (elslyxmzjw ) View more	Positive	05 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis